echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Not to be outdone, Novartis KRAS China gets clinical approval; domestic competition pattern

    Not to be outdone, Novartis KRAS China gets clinical approval; domestic competition pattern

    • Last Update: 2021-04-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Note: This article does not constitute any investment opinions and suggestions,and is subject to the companyis announcement;this article is only an introduction to medical and health-related drugs, and non-treatment plan recommendations (if involved).Recently, JDQ443 tablets declared by Novartis Pharma AG/Novartis (China) Biomedical Research Co., Ltd., with acceptance number JXHL2100016/JXHL2100017,are intended to be targeted for the indication of KRAS G12C mutation in advanced solid tumors.In this target field, other foreign pharmaceutical giants MNC have received clinical approval in China: Amgenis new drug candidate AMG510 (Sotorasib),and Boehringer Ingelheim (BI)is BI1701963 (a new oral pan-KRAS inhibitor).

    Yifang Biological

    Yifang Biology has initiated Phase 1/2 clinical trials of the new drug D-1553 overseas, and plans to recruit 200 patients with NSCLC and CRC tumors.ClinicalTrials.gov clinical registration number: NCT04585035, the earliest registration was October 14, 2020.This product may be the fastest new KRAS G12C drug developed in China to enter the clinic.The IND application submitted in China has been clinically approved.

    Betta Pharmaceuticals

    The domestic clinical trial application for the KRAS-G12C inhibitor BPI-421286 was announced by CDE on January 22, 2021, and clinical trials are expected to be approved in the near future.

    First Pharmaceutical Holdings

    Beijing First Pharmaceutical Holdings (Beijing) Co., Ltd. was established on April 19, 2016. It is a mixed-ownership high-tech enterprise with shares held by municipal and district state-owned funds. The company is headquartered in Jingyuan Street, Yizhuang Economic and Technological Development Zone, Beijing, focusing on the R&D and production of innovative drugs with independent intellectual property rights. Recently applied for listing on the Science and Technology Innovation Board, and the prospectus indicated that the company has a KRAS inhibitor under development.

    Jinfang Medicine

    Jinfang Pharmaceutical Technology (Shanghai) Co., Ltd. was established in 2017. With immunology as the core, the company focuses on multiple therapeutic areas such as tumors and autoimmune diseases. Currently, the new drug varieties independently developed are all original "global new" products, addressing the major unmet clinical needs of patients in China and the world. It has sufficient technical advantages and huge market space. It is reported that Jinfang Medicine is developing a KRAS G12C inhibitor, and the related patent WO/2020/177629 "Spirocyclic substituted pyrimidocyclic compounds, their preparation and medical use" has been published.

    Gacos

    The KRAS G12C inhibitor of Beijing Jiaxi New Drug Research and Development Co., Ltd. is expected to submit an IND in 2021 soon.

    Microbiology

    Established in April 2018, Microenvironment is a biomedical high-tech company dedicated to the research and development of innovative drugs. It is mainly engaged in small molecule anti-tumor drugs and PROTAC, covalent / allosteric, drug coupling and other small molecule new technology platforms. Development. Microenvironment Biosciences applied for a Chinese patent for KRAS inhibitors in June 2019, and published a patent CN110256421A on September 20.

    Nanjing Mingde

    On July 25, 2019, WuXi AppTec is wholly-owned subsidiary Nanjing Mingde New Drug Research and Development Co., Ltd. published a compound patent for a KRAS G12C inhibitor. The WO2019141250(A1) patent was first applied for in January 2019. It is reported that the rights and interests of the product have been transferred to the domestic new drug company.

    SINOVI

    Cignovi was founded in 2017. Relying on its Suzhou headquarters, it has established two branches in Shanghai and Beijing, and has two wholly-owned subsidiaries in Australia and the United States. Cignovi draws on excellent global standards and has a profound understanding of the Chinese market. Understanding and continuous investment, committed to bringing the most advanced drugs to the market at a faster speed and providing them to more patients to meet the ever-increasing medical needs. At present, Sinovio has 12 products under development, covering multiple therapeutic areas such as tumor, autoimmunity, anti-infection, and metabolism. A KRAS inhibitor compound, related domestic patent CN111377918A, publication date: July 7, 2020.

    Bibet

    Bibate Pharmaceutical was co-founded by Dr. Qian Changgeng and his team in March 2012. It is a completely innovative first-class new drug research and development company. Its product line indications cover lymphoma, breast cancer, lung cancer, ovarian cancer and other blood tumors and solid tumors. And non-alcoholic steatohepatitis (NASH), psoriasis and other major diseases. Currently BEBT-607 is a KRAS G12C inhibitor.

    Ellis

    Aires is an innovative drug company focusing on the field of tumor treatment. It has built a rich R&D pipeline in the field of small molecule targeted drugs for non-small cell lung cancer. KRAS G12C inhibitors are currently in the preclinical stage.

    Other research companies include

    Shanghai Yingli Pharmaceutical Co., Ltd. (YL-15293), Lingji Biological, Luye Pharmaceutical, Deqi Pharmaceutical (ATG-012), Guangdong Xinqi Biomedicine, Haibowei, Hangzhou Duoyu, Enrui Biological, China Pharmaceutical University, PhD, etc. In addition, there are some companies under research that have not been made public.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.